



<b>CCRT</b>	13	Reference			-	-		-		
<b>Chemotherapy only</b>	95	1.52	0.66-3.53	0.328	2.47	1.00-6.14	0.051	1.71	0.61-4.76	0.305
<b>Neoadjuvant cycle<sup>a)</sup></b>	104	1.08	0.89-1.31	0.429	0.93	0.76-1.13	0.462	1.00	0.79-1.27	0.982
<b>Adjuvant therapy<sup>a)</sup></b>	108									
<b>No</b>	30	Reference			-	-		-		
<b>Yes</b>	78	1.27	0.72-2.25	0.409	2.08	1.16-3.72	0.014	1.81	0.87-3.73	0.111
<b>Pleural invasion<sup>a)</sup></b>	108									
<b>Absent</b>	66	Reference			-	-		-		
<b>Present</b>	42	1.49	0.90-2.45	0.118	1.49	0.94-2.34	0.088	1.43	0.81-2.54	0.217
<b>Lymphovascular invasion<sup>a)</sup></b>	108									
<b>Absent</b>	32	Reference			-	-		-		
<b>Present</b>	76	1.83	1.01-3.32	0.047	3.03	1.70-5.39	<0.001	2.23	1.08-4.61	0.030
<b>Perineural invasion<sup>a)</sup></b>	108									
<b>Absent</b>	90	Reference			-	-		-		
<b>Present</b>	18	2.20	1.21-4.00	0.010	1.45	0.79-2.64	0.227	2.24	1.14-4.42	0.020
<b>STAS<sup>a)</sup></b>	108									
<b>Absent</b>	60	Reference			-	-		-		
<b>Grade I</b>	24	1.40	0.76-2.58	0.286	1.56	0.88-2.75	0.125	1.73	0.87-3.44	0.119
<b>Grade II</b>	24	1.48	0.81-2.70	0.204	2.85	1.65-4.91	<0.001	1.68	0.85-3.34	0.139
<b>MPR status</b>	108									
<b>MPR -</b>	90	Reference			-	-		-		
<b>MPR +</b>	18	0.37	0.16-0.87	0.023	0.25	0.11-0.57	0.001	0.16	0.04-0.68	0.012
<b>VT (%)</b>	108	1.01	1.00-1.02	0.089	1.01	1.01-1.02	<0.001	1.01	1.00-1.02	0.036
<b>Necrosis (%)</b>	108	0.99	0.98-1.01	0.591	0.99	0.98-1.01	0.357	0.97	0.94-1.00	0.064
<b>Stroma (%)</b>	108	0.99	0.98-1.00	0.167	0.99	0.98-1.00	0.011	1.00	0.98-1.01	0.384

ADC, adenocarcinoma; CCRT, concurrent chemoradiation therapy; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; LCS, lung cancer-specific survival; MPR, major pathologic response; OS, overall survival; SqCC, squamous cell carcinoma; STAS, spread through air space; VT, viable tumor.

<sup>a)</sup>Variables found to have a significant ( $p < 0.05$ ) relationship with MPR and these were not included in multivariable analysis. Viable tumor, necrosis, and stroma were calculated in tumor bed area-weighted manner.